REDWOOD CITY, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that it will present at two upcoming investor conferences. Russell Howard, Maxygen’s chief executive officer, will present.
A live webcast of the presentations can be accessed on Maxygen’s website at http://www.maxygen.com/webcasts. A replay of the presentations will be available for approximately 30 days.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen’s approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
CONTACT: Michele Boudreau, Investor and Public Relations of Maxygen, Inc.,
+1-650-279-2088, michele.boudreau@maxygen.com
Web site: http://www.maxygen.com/
